

REFERENCES

- Alghasham, A.A., 2013. Cucurbitacins : A Promising Target for Cancer Therapy. *Int. J. Health Sci.* 7, 77–89. <https://doi.org/10.12816/0006025>
- Arteaga, C.L., Engelman, J.A., 2014. ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. *Cancer Cell* 25, 282–303. <https://doi.org/10.1016/j.ccr.2014.02.025>
- Awrahman, H.A., Mohamad, D., 2024. Advanced breast cancer diagnosis: Multiplex RT-qPCR for precise typing and angiogenesis profiling. *Biochem. Biophys. Rep.* 37, 101615. <https://doi.org/10.1016/j.bbrep.2023.101615>
- Benz, C.C., Scott, G.K., Sarup, J.C., Johnson, R.M., Tripathy, D., Coronado, E., Shepard, H.M., Osborne, C.K., 1992. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. *Breast Cancer Res. Treat.* 24, 85–95. <https://doi.org/10.1007/BF01961241>
- Bergholz, J.S., Zhao, J.J., 2021. How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic Resistance in Cancer. *Cancer Res.* 81, 6074–6077. <https://doi.org/10.1158/0008-5472.CAN-21-3605>
- Birbo, B., Madu, E.E., Madu, C.O., Jain, A., Lu, Y., 2021. Role of HSP90 in Cancer. *Int. J. Mol. Sci.* 22, 10317. <https://doi.org/10.3390/ijms221910317>
- Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J.J., Spratt, D.E., Viola-Villegas, N.T., Castel, P., Minuesa, G., Morse, N., Rodón, J., Ibrahim, Y., Cortes, J., Perez-Garcia, J., Galvan, P., Grueso, J., Guzman, M., Katzenellenbogen, J.A., Kharas, M., Lewis, J.S., Dickler, M., Serra, V., Rosen, N., Chandarlapaty, S., Scaltriti, M., Baselga, J., 2015. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. *Sci. Transl. Med.* 7, 283ra51. <https://doi.org/10.1126/scitranslmed.aaa4442>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and

- mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 68, 394–424. <https://doi.org/10.3322/caac.21492>
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., Jemal, A., 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 74, 229–263. <https://doi.org/10.3322/caac.21834>
- Brouwer, I.J., Out-Luiting, J.J., Vermeer, M.H., Tensen, C.P., 2020. Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells. *Biochem. Biophys. Rep.* 24, 100832. <https://doi.org/10.1016/j.bbrep.2020.100832>
- Cao, W., Li, X., Zheng, S., Zheng, W., Wong, Y., Chen, T., 2014. Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk. *Oncotarget* 5, 7431–7445. <https://doi.org/10.18632/oncotarget.2008>
- Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M.S., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G.S., Biganzoli, L., Boyle, F., Cardoso, M.-J., Carey, L.A., Cortés, J., Saghir, N.S.E., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P.A., Gelmon, K., Gligorov, J., Haidinger, R., Harbeck, N., Hu, X., Kaufman, B., Kaur, R., Kiely, B.E., Kim, S.-B., Lin, N.U., Mertz, S.A., Neciosup, S., Offersen, B.V., Ohno, S., Pagani, O., Prat, A., Penault-Llorca, F., Rugo, H.S., Sledge, G.W., Thomssen, C., Vorobiof, D.A., Wiseman, T., Xu, B., Norton, L., Costa, A., Winer, E.P., 2020. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). *Ann. Oncol.* 31, 1623–1649. <https://doi.org/10.1016/j.annonc.2020.09.010>
- Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P.K., Baselga, J., Rosen, N., 2011. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. *Cancer Cell* 19, 58–71. <https://doi.org/10.1016/j.ccr.2010.10.031>

- Cheng, Q., Chang, J.T., Geradts, J., Neckers, L.M., Haystead, T., Spector, N.L., Lyerly, H.K., 2012. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. *Breast Cancer Res. BCR* 14, R62. <https://doi.org/10.1186/bcr3168>
- Cheng, X., 2024. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. *Genes* 15, 903. <https://doi.org/10.3390/genes15070903>
- Chia, S.K., Ellard, S.L., Mates, M., Welch, S., Mihalcioiu, C., Miller, W.H., Gelmon, K., Lohrisch, C., Kumar, V., Taylor, S., Hagerman, L., Goodwin, R., Wang, T., Sakashita, S., Tsao, M.S., Eisenhauer, E., Bradbury, P., 2017. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. *Breast Cancer Res.* 19, 54. <https://doi.org/10.1186/s13058-017-0836-3>
- Chin, C.-H., Chen, S.-H., Wu, H.-H., Ho, C.-W., Ko, M.-T., Lin, C.-Y., 2014. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst. Biol.* 8, S11. <https://doi.org/10.1186/1752-0509-8-S4-S11>
- Clark, A.J., Lillard, J.W., 2024. A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology. *Genes* 15, 1036. <https://doi.org/10.3390/genes15081036>
- Clough, E., Barrett, T., 2016. The Gene Expression Omnibus Database, in: Mathé, E., Davis, S. (Eds.), *Statistical Genomics, Methods in Molecular Biology*. Springer New York, New York, NY, pp. 93–110. https://doi.org/10.1007/978-1-4939-3578-9_5
- D'Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., Bianco, R., 2015. Mechanisms of lapatinib resistance in HER2-driven breast cancer. *Cancer Treat. Rev.* 41, 877–883. <https://doi.org/10.1016/j.ctrv.2015.08.001>

- Diaz, J.E., Ahsen, M.E., Schaffter, T., Chen, X., Realubit, R.B., Karan, C., Califano, A., Losic, B., Stolovitzky, G., 2020. The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies. *eLife* 9, e52707. <https://doi.org/10.7554/eLife.52707>
- Duarte, D., Vale, N., 2022. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. *Curr. Res. Pharmacol. Drug Discov.* 3, 100110. <https://doi.org/10.1016/j.crphar.2022.100110>
- Edge, S.B., American Joint Committee on Cancer (Eds.), 2010. *AJCC cancer staging manual*, 7th ed. ed. Springer, New York, NY.
- Eichhorn, P.J.A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R.L., Valero, V., Seoane, J., Bernards, R., Baselga, J., 2008. Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. *Cancer Res.* 68, 9221–9230. <https://doi.org/10.1158/0008-5472.CAN-08-1740>
- Eustace, A.J., Conlon, N.T., McDermott, M.S.J., Browne, B.C., O’Leary, P., Holmes, F.A., Espina, V., Liotta, L.A., O’Shaughnessy, J., Gallagher, C., O’Driscoll, L., Rani, S., Madden, S.F., O’Brien, N.A., Ginther, C., Slamon, D., Walsh, N., Gallagher, W.M., Zagozdzon, R., Watson, W.R., O’Donovan, N., Crown, J., 2018. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. *BMC Cancer* 18, 965. <https://doi.org/10.1186/s12885-018-4852-1>
- Figueroa-Magalhães, M.C., Jelovac, D., Connolly, R.M., Wolff, A.C., 2014. Treatment of HER2-positive breast cancer. *The Breast* 23, 128–136. <https://doi.org/10.1016/j.breast.2013.11.011>
- Fox, M., Mott, H.R., Owen, D., 2020. Class IA PI3K regulatory subunits: p110-independent roles and structures. *Biochem. Soc. Trans.* 48, 1397–1417. <https://doi.org/10.1042/BST20190845>
- Gadgeel, S.M., Lew, D.L., Synold, T.W., LoRusso, P., Chung, V., Christensen, S.D., Smith, D.C., Kingsbury, L., Hoering, A., Kurzrock, R., 2013. Phase I

study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. *Cancer Chemother. Pharmacol.* 72, 1089–1096. <https://doi.org/10.1007/s00280-013-2297-4>

Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Cerami, E., Sander, C., Schultz, N., 2013. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. *Sci. Signal.* 6. <https://doi.org/10.1126/scisignal.2004088>

Garrett, J.T., Olivares, M.G., Rinehart, C., Granja-Ingram, N.D., Sánchez, V., Chakrabarty, A., Dave, B., Cook, R.S., Pao, W., McKinley, E., Manning, H.C., Chang, J., Arteaga, C.L., 2011. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. *Proc. Natl. Acad. Sci.* 108, 5021–5026. <https://doi.org/10.1073/pnas.1016140108>

Gautama, W., 2022. Breast Cancer in Indonesia in 2022: 30 Years of Marching in Place. *Indones. J. Cancer* 16, 1. <https://doi.org/10.33371/ijoc.v16i1.920>

Giaquinto, A.N., Sung, H., Newman, L.A., Freedman, R.A., Smith, R.A., Star, J., Jemal, A., Siegel, R.L., 2024. Breast cancer statistics 2024. *CA. Cancer J. Clin.* 74, 477–495. <https://doi.org/10.3322/caac.21863>

Györfy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., Szallasi, Z., 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Res. Treat.* 123, 725–731. <https://doi.org/10.1007/s10549-009-0674-9>

He, Y., Sun, M.M., Zhang, G.G., Yang, J., Chen, K.S., Xu, W.W., Li, B., 2021. Targeting PI3K/Akt signal transduction for cancer therapy. *Signal Transduct. Target. Ther.* 6, 425. <https://doi.org/10.1038/s41392-021-00828-5>

- Hermawan, A., Ikawati, M., Jenie, R.I., Khumaira, A., Putri, H., Nurhayati, I.P., Angraini, S.M., Muflikhasari, H.A., 2021. Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies. *Saudi Pharm. J.* 29, 12–26. <https://doi.org/10.1016/j.jsps.2020.12.002>
- Hermawan, A., Putri, H., Utomo, R.Y., 2020. Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance. *Mol. Divers.* 24, 933–947. <https://doi.org/10.1007/s11030-019-10003-2>
- Hermawan, A., Uche, S., Ibadurrahman, W., Ardi, K.P., Djerico, C., 2024. Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development, in: Rezaei, N. (Ed.), *Breast Cancer Genetics, Immunology, and Immunotherapy: An Interdisciplinary Approach, Interdisciplinary Cancer Research*. Springer Nature Switzerland, Cham, pp. 377–431. https://doi.org/10.1007/16833_2024_246
- Hsu, P., Tian, B., Yang, Y., Wang, Y., Liu, S., Urisman, A., Yang, C., Xu, Z., Jablons, D., You, L., 2019. Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model. *Oncol. Rep.* <https://doi.org/10.3892/or.2019.7207>
- Ignatov, A., Eggemann, H., Burger, E., Ignatov, T., 2018. Patterns of breast cancer relapse in accordance to biological subtype. *J. Cancer Res. Clin. Oncol.* 144, 1347–1355. <https://doi.org/10.1007/s00432-018-2644-2>
- Iqbal, Nida, Iqbal, Naveed, 2014. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. *Mol. Biol. Int.* 2014, 1–9. <https://doi.org/10.1155/2014/852748>
- Jodynys-Liebert, J., Kujawska, M., 2020. Biphasic Dose-Response Induced by Phytochemicals: Experimental Evidence. *J. Clin. Med.* 9, 718. <https://doi.org/10.3390/jcm9030718>

- Kaczyńska, A., Herman-Antosiewicz, A., 2017. Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells. *Breast Cancer* 24, 271–280. <https://doi.org/10.1007/s12282-016-0700-9>
- Kanehisa Laboratories, 2020. KEGG PATHWAY: Pathways in cancer - Homo sapiens (human) [WWW Document]. KEGG Pathw. URL <https://www.kegg.jp/pathway/hsa05200> (accessed 7.13.26).
- Kanehisa Laboratories, 2016. KEGG PATHWAY: EGFR tyrosine kinase inhibitor resistance - Reference pathway [WWW Document]. URL <https://www.kegg.jp/pathway/map01521> (accessed 7.29.26).
- Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M., Ishiguro-Watanabe, M., 2023. KEGG for taxonomy-based analysis of pathways and genomes. *Nucleic Acids Res.* 51, D587–D592. <https://doi.org/10.1093/nar/gkac963>
- Khatoon, E., Banik, K., Harsha, C., Sailo, B.L., Thakur, K.K., Khwairakpam, A.D., Vikkurthi, R., Devi, T.B., Gupta, S.C., Kunnumakkara, A.B., 2022. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. *Semin. Cancer Biol.* 80, 306–339. <https://doi.org/10.1016/j.semcancer.2020.06.014>
- Kim, H.J., Eom, Y.H., Choi, S.H., 2023. Prognostic influences of B-cell lymphoma 2–positive expression on late recurrence in breast cancer. *Ann. Surg. Treat. Res.* 105, 20–30. <https://doi.org/10.4174/astr.2023.105.1.20>
- Konecny, G.E., Pegram, M.D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D.W., Spehar, G., Mullin, R.J., Keith, B.R., Gilmer, T.M., Berger, M., Podratz, K.C., Slamon, D.J., 2006. Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. *Cancer Res.* 66, 1630–1639. <https://doi.org/10.1158/0008-5472.CAN-05-1182>
- Kong, Y., Chen, J., Zhou, Z., Xia, H., Qiu, M.-H., Chen, C., 2014. Cucurbitacin E Induces Cell Cycle G2/M Phase Arrest and Apoptosis in Triple Negative Breast Cancer. *PLoS ONE* 9, e103760. <https://doi.org/10.1371/journal.pone.0103760>

- Kuhn, M., Von Mering, C., Campillos, M., Jensen, L.J., Bork, P., 2007. STITCH: interaction networks of chemicals and proteins. *Nucleic Acids Res.* 36, D684–D688. <https://doi.org/10.1093/nar/gkm795>
- Lan, T., Wang, L., Xu, Q., Liu, W., Jin, H., Mao, W., Wang, Xian, Wang, Xiaojia, 2013. Growth inhibitory effect of Cucurbitacin E on breast cancer cells Vol. 6, Issue 9.
- Lee, A.V., Oesterreich, S., Davidson, N.E., 2015. MCF-7 Cells—Changing the Course of Breast Cancer Research and Care for 45 Years | *JNCI: Journal of the National Cancer Institute* | Oxford Academic [WWW Document]. URL <https://academic.oup.com/jnci/article-abstract/107/7/djv073/912073?redirectedFrom=fulltext#no-access-message> (accessed 7.13.26).
- Liao, Y., Wang, J., Jaehnig, E.J., Shi, Z., Zhang, B., 2019. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res.* 47, W199–W205. <https://doi.org/10.1093/nar/gkz401>
- Lin, S., Chang, C., Hsu, C., Tsai, M., Cheng, H., Leong, M.K., Sung, P., Chen, J., Weng, C., 2020. Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence. *Br. J. Pharmacol.* 177, 1409–1423. <https://doi.org/10.1111/bph.14816>
- Liu, Y., Yang, H., Guo, Q., Liu, T., Jiang, Y., Zhao, M., Zeng, K., Tu, P., 2020. Cucurbitacin E Inhibits Huh7 Hepatoma Carcinoma Cell Proliferation and Metastasis via Suppressing MAPKs and JAK/STAT3 Pathways. *Molecules* 25, 560. <https://doi.org/10.3390/molecules25030560>
- Luo, J., Zou, H., Guo, Y., Tong, T., Ye, L., Zhu, C., Deng, L., Wang, B., Pan, Y., Li, P., 2022. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. *Breast Cancer Res.* 24, 99. <https://doi.org/10.1186/s13058-022-01596-y>
- Manning, B.D., Toker, A., 2017. AKT/PKB Signaling: Navigating the Network. *Cell* 169, 381–405. <https://doi.org/10.1016/j.cell.2017.04.001>
- Marostica, L.L., Silva, I.T., Kratz, J.M., Persich, L., Geller, F.C., Lang, K.L., Caro, M.S.B., Durán, F.J., Schenkel, E.P., Simões, C.M.O., 2015. Synergistic

- Antiproliferative Effects of a New Cucurbitacin B Derivative and Chemotherapy Drugs on Lung Cancer Cell Line A549. *Chem. Res. Toxicol.* 28, 1949–1960. <https://doi.org/10.1021/acs.chemrestox.5b00153>
- Nurhayati, I.P., Khumaira, A., Ilmawati, G.P.N., Meiyanto, E., Hermawan, A., 2020. Cytotoxic and Antimetastatic Activity of Hesperetin and Doxorubicin Combination Toward Her2 Expressing Breast Cancer Cells. *Asian Pac. J. Cancer Prev.* 21, 1259–1267. <https://doi.org/10.31557/APJCP.2020.21.5.1259>
- Orrantia-Borunda, E., Acuña-Aguilar, L.E., Ramírez-Valdespino, C.A., 2022. Nanomaterials for Breast Cancer, in: Mayrovitz, H.N. (Ed.), *Breast Cancer*. Exon Publications, Brisbane (AU).
- Pan, L., Li, J., Xu, Q., Gao, Z., Yang, M., Wu, X., Li, X., 2024. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review. *Medicine (Baltimore)* 103, e38508. <https://doi.org/10.1097/MD.00000000000038508>
- Pan, S.-Y., Zhou, S.-F., Gao, S.-H., Yu, Z.-L., Zhang, S.-F., Tang, M.-K., Sun, J.-N., Ma, D.-L., Han, Y.-F., Fong, W.-F., Ko, K.-M., 2013. New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics. *Evid. Based Complement. Alternat. Med.* 2013, 1–25. <https://doi.org/10.1155/2013/627375>
- Parsons, S.J., Parsons, J.T., 2004. Src family kinases, key regulators of signal transduction. *Oncogene* 23, 7906–7909. <https://doi.org/10.1038/sj.onc.1208160>
- Pawlus, M., Wang, L., Hu, C.-J., 2014. STAT3 and HIF1 α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. *Oncogene* 33, 1670–1679. <https://doi.org/10.1038/onc.2013.115>
- Putra, I.M.R., Lestari, I.A., Fatimah, N., Hanif, N., Ujiantari, N.S.O., Putri, D.D.P., Hermawan, A., 2024. Bioinformatics and In Vitro Study Reveal ER α as The Potential Target Gene of Honokiol to Enhance Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer Cells. *Comput. Biol. Chem.* 111, 108084. <https://doi.org/10.1016/j.compbiolchem.2024.108084>

- Rajendran, V., Jain, M.V., 2018. In Vitro Tumorigenic Assay: Colony Forming Assay for Cancer Stem Cells. *Methods Mol. Biol.* 1692, 89–95. https://doi.org/10.1007/978-1-4939-7401-6_8
- Rexer, B.N., Arteaga, C.L., 2012. Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications. *Crit. Rev. Oncog.* 17, 1–16. <https://doi.org/10.1615/CritRevOncog.v17.i1.20>
- Riss, T.L., Moravec, R.A., Niles, A.L., Benink, H.A., Worzella, T.J., Minor, L., 2013. Cell Viability Assays.
- Ruiz-Saenz, A., Dreyer, C., Campbell, M.R., Steri, V., Gulizia, N., Moasser, M.M., 2018. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. *Cancer Res.* 78, 3645–3658. <https://doi.org/10.1158/0008-5472.CAN-18-0430>
- Saeed, M.E.M., Boulos, J.C., Elhaboub, G., Rigano, D., Saab, A., Loizzo, M.R., Hassan, L.E.A., Sugimoto, Y., Piacente, S., Tundis, R., Yagi, S., Khalid, H., Efferth, T., 2019. Cytotoxicity of cucurbitacin E from *Citrullus colocynthis* against multidrug-resistant cancer cells. *Phytomedicine* 62, 152945. <https://doi.org/10.1016/j.phymed.2019.152945>
- Saxena, A.R., Ilic, Z., Sripada, V., Crawford, D.R., 2020. Lower concentrations of curcumin inhibit Her2-Akt pathway components in human breast cancer cells, and other dietary botanicals potentiate this and lapatinib inhibition. *Nutr. Res.* 78, 93–104. <https://doi.org/10.1016/j.nutres.2020.05.007>
- Sayers, E.W., Bolton, E.E., Brister, J.R., Canese, K., Chan, J., Comeau, D.C., Connor, R., Funk, K., Kelly, C., Kim, S., Madej, T., Marchler-Bauer, A., Lanczycki, C., Lathrop, S., Lu, Z., Thibaud-Nissen, F., Murphy, T., Phan, L., Skripchenko, Y., Tse, T., Wang, J., Williams, R., Trawick, B.W., Pruitt, K.D., Sherry, S.T., 2022. Database resources of the national center for biotechnology information. *Nucleic Acids Res.* 50, D20–D26. <https://doi.org/10.1093/nar/gkab1112>
- SEER Cancer Stat Facts: Female Breast Cancer. Surveillance, Epidemiology, and End Results Program. Data for five-year relative survival: SEER 21,

- excluding Illinois, 2016–2022. [WWW Document], n.d. . SEER. URL <https://seer.cancer.gov/statfacts/html/breast.html> (accessed 7.28.26).
- Semenza, G.L., 2012. Hypoxia-inducible factors in physiology and medicine - PubMed [WWW Document]. URL <https://pubmed.ncbi.nlm.nih.gov/22304911/> (accessed 7.12.26).
- Sharma, J.D., Khanna, S., Ramchandani, S., Kakoti, L.M., Baruah, A., Mamidala, V., 2021. Prevalence of Molecular Subtypes of Breast Carcinoma and Its Comparison between Two Different Age Groups: A Retrospective Study from a Tertiary Care Center of Northeast India. *South Asian J. Cancer* 10, 220–224. <https://doi.org/10.1055/s-0041-1731905>
- Si, W., Lyu, J., Liu, Z., Wang, C., Huang, J., Jiang, L., Ma, T., 2019. Cucurbitacin E inhibits cellular proliferation and enhances the chemo-response in gastric cancer by suppressing AKt activation. *J. Cancer* 10, 5843–5851. <https://doi.org/10.7150/jca.31303>
- Siddiqua, A., Long, L.M., Li, L., Marciniak, R.A., Kazhdan, I., 2008. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. *BMC Cancer* 8, 129. <https://doi.org/10.1186/1471-2407-8-129>
- Sleightholm, R., Neilsen, B.K., Elkhatib, S., Flores, L., Dukkupati, S., Zhao, R., Choudhury, S., Gardner, B., Carmichael, J., Smith, L., Bennion, N., Wahl, A., Baine, M., 2021. Percentage of Hormone Receptor Positivity in Breast Cancer Provides Prognostic Value: A Single-Institute Study. *J. Clin. Med. Res.* 13, 9–19. <https://doi.org/10.14740/jocmr4398>
- Sörensen, P.M., Iacob, R.E., Fritzsche, M., Engen, J.R., Briher, W.M., Charras, G., Eggert, U.S., 2012. The natural product cucurbitacin E inhibits depolymerization of actin filaments. *ACS Chem. Biol.* 7, 1502–1508. <https://doi.org/10.1021/cb300254s>
- Sun, C., Zhang, M., Shan, X., Zhou, X., Yang, J., Wang, Y., Li-Ling, J., Deng, Y., 2010. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth

- via STAT3 signaling. *J. Cancer Res. Clin. Oncol.* 136, 603–610.
<https://doi.org/10.1007/s00432-009-0698-x>
- Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A.L., Fang, T., Doncheva, N.T., Pyysalo, S., Bork, P., Jensen, L.J., von Mering, C., 2023. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res.* 51, D638–D646.
<https://doi.org/10.1093/nar/gkac1000>
- Trepel, J., Mollapour, M., Giaccone, G., Neckers, L., 2010. Targeting the dynamic HSP90 complex in cancer. *Nat. Rev. Cancer* 10, 537–549.
<https://doi.org/10.1038/nrc2887>
- Üremiş, M.M., Üremiş, N., Türköz, Y., 2023. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways. *Steroids* 198, 109261.
<https://doi.org/10.1016/j.steroids.2023.109261>
- Van Meerloo, J., Kaspers, G.J.L., Cloos, J., 2011. Cell Sensitivity Assays: The MTT Assay, in: Cree, I.A. (Ed.), *Cancer Cell Culture, Methods in Molecular Biology*. Humana Press, Totowa, NJ, pp. 237–245.
https://doi.org/10.1007/978-1-61779-080-5_20
- Vazquez-Martin, A., Oliveras-Ferraro, C., Colomer, R., Brunet, J., Menendez, J.A., 2008. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* 19, 1097–1109.
<https://doi.org/10.1093/annonc/mdm589>
- Vinod, B.S., Nair, H.H., Vijayakurup, V., Shabna, A., Shah, S., Krishna, A., Pillai, K.S., Thankachan, S., Anto, R.J., 2015. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis. *Cell Death Discov.* 1, 15061. <https://doi.org/10.1038/cddiscovery.2015.61>

- Vivekanandhan, S., Knutson, K.L., 2022. Resistance to Trastuzumab. *Cancers* 14, 5115. <https://doi.org/10.3390/cancers14205115>
- Wang, L., Xu, H., Li, X., Chen, H., Zhang, Haigang, Zhu, X., Lin, Z., Guo, S., Bao, Z., Rui, H., He, W., Zhang, Hui, 2023. Cucurbitacin E reduces IL-1 β -induced inflammation and cartilage degeneration by inhibiting the PI3K/Akt pathway in osteoarthritic chondrocytes. *J. Transl. Med.* 21, 880. <https://doi.org/10.1186/s12967-023-04771-7>
- Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z., Wang, B., Shao, Z., Wang, Z., Hu, X., 2011. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. *BMC Cancer* 11, 248. <https://doi.org/10.1186/1471-2407-11-248>
- Wang, W., He, Y.-F., Sun, Q.-K., Wang, Y., Han, X.-H., Peng, D.-F., Yao, Y.-W., Ji, C.-S., Hu, B., 2014. Hypoxia-inducible factor 1 α in breast cancer prognosis. *Clin. Chim. Acta Int. J. Clin. Chem.* 428, 32–37. <https://doi.org/10.1016/j.cca.2013.10.018>
- Wang, Y.-C., Morrison, G., Gillihan, R., Guo, J., Ward, R.M., Fu, X., Botero, M.F., Healy, N.A., Hilsenbeck, S.G., Phillips, G.L., Chamness, G.C., Rimawi, M.F., Osborne, C.K., Schiff, R., 2011. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation. *Breast Cancer Res. BCR* 13, R121. <https://doi.org/10.1186/bcr3067>
- Wee, P., Wang, Z., 2017. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers* 9, 52. <https://doi.org/10.3390/cancers9050052>
- Wei, F., Zhang, Y., Geng, L., Zhanng, P., Wang, G., Liu, Y., 2015. mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer [WWW Document]. URL <https://www.mdpi.com/1422-0067/16/2/3267> (accessed 7.13.26).
- Wisinski, K.B., Tevaarwerk, A.J., Burkard, M.E., Rampurwala, M., Eickhoff, J., Bell, M.C., Kolesar, J.M., Flynn, C., Liu, G., 2016. Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. *Clin.*

- Cancer Res. 22, 2659–2667. <https://doi.org/10.1158/1078-0432.CCR-15-2365>
- Xia, X., 2017. Bioinformatics and Drug Discovery. Curr. Top. Med. Chem. 17, 1709–1726. <https://doi.org/10.2174/1568026617666161116143440>
- Ye, M., Huang, W., Liu, R., Kong, Y., Liu, Y., Chen, X., Xu, J., 2021. Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells. Front. Pharmacol. 12, 651516. <https://doi.org/10.3389/fphar.2021.651516>
- Yu, H., Lee, H., Herrmann, A., Buettner, R., Jove, R., 2014. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14, 736–746. <https://doi.org/10.1038/nrc3818>
- Zhang, R., Qiao, H., Chen, S., Chen, X., Dou, K., Wei, L., Zhang, J., 2016. Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. Cancer Biol. Ther. 17, 925–934. <https://doi.org/10.1080/15384047.2016.1210728>
- Zhang, T., Li, J., Dong, Y., Zhai, D., Lai, L., Dai, F., Deng, H., Chen, Y., Liu, M., Yi, Z., 2012. Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res. Treat. 135, 445–458. <https://doi.org/10.1007/s10549-012-2175-5>
- Zhao, Z., Mu, H., Li, Y., Liu, Y., Zou, J., Zhu, Y., 2020. Clinicopathological and prognostic value of hypoxia-inducible factor-1 α in breast cancer: a meta-analysis including 5177 patients. Clin. Transl. Oncol. 22, 1892–1906. <https://doi.org/10.1007/s12094-020-02332-8>